Back to Journals » OncoTargets and Therapy » Volume 6

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers

Total article views   HTML views PDF downloads Totals
18,996 Dovepress* 13,528+ 3,428 16,956
PubMed Central* 5,468 1,872 7,340
Totals 18,996 5,300 24,296
*Since 5 November 2013
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 0 5

View citations on PubMed Central and Google Scholar